



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,077	12/29/2005	Ernest P. Noble	UCLA.154-US-WO	3519
59612	7590	01/12/2009		
KAREN S. CANADY CANADY & LORTZ LLP COMMERCE PLAZA 11340 WEST OLYMPIC BLVD., SUITE 275 LOS ANGELES, CA 90064			EXAMINER LUNDGREN, JEFFREY S	
			ART UNIT 1639	PAPER NUMBER
			NOTIFICATION DATE 01/12/2009	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

KAREN@CANADYLORTZ.COM
adriane@canadylortz.com
kayruun@gmail.com

Office Action Summary	Application No. 10/563,077	Applicant(s) NOBLE ET AL.	
	Examiner JEFFREY S. LUNDGREN	Art Unit 1639	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 October 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) 3 and 4 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 2 and 5-8 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1639

DETAILED ACTION

Status of the Claims

Claims 1-8 are pending in the instant application; claims 3 and 4 are withdrawn as being directed to a non-elected species; claims 1, 2 and 5-8 are the subject of the Office Action below.

Claim Rejections - 35 USC § 112, first paragraph (New Matter) – Maintained

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 1, 2, 5 and 6, and newly added claims 7 and 8, under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for containing new matter, is maintained. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

Applicants traverse the rejection and allege that the specification contains adequate support for the claim language. Applicants assert that:

“Patients having the TaqIA (A1) allele (A1+ allelic status) are candidates for treatment with **high dose of high D2 dopamine receptor binding antipsychotics** and/or SSRIs that influence D2 dopamine receptor density, Patients lacking the TaqIA allele (A1- allelic status) are not likely to respond well to these SSRIs, and are candidates for treatment with **low dose of low D2 dopamine receptor binding or tow dose high D2 dopamine receptor binding atypical antipsychotics.**”

Reply, page 4 (emphasis in original). Applicants allege that the difference of the “high dose” and “low dose” language as captioned above is a typographical error that one of ordinary skill in the art would easily recognize. Applicants do not comment on the lack of the “atypical antipsychotic” limitation in this section of the specification. Applicants further allege that this mistake is apparent because of the discussion pertaining to paragraphs 0049, 0003, 0050, 0052, 0060, 0063 and 0110.

Applicants arguments have been fully considered, however, are not found persuasive.

Art Unit: 1639

As stated previously, claim 1 contains new matter for reciting the limitation:

“an *A1+* genotype is indicative of a candidate for treatment with ***low dose*** DRD2 binding atypical antipsychotics and/or SSRIs that increase D2 dopamine receptor density;”

and the limitation:

“an *A1-* genotype is indicative of a candidate for treatment with high dose D2 dopamine receptor binding atypical antipsychotics or alternative antidepressant.”

These limitations are in direct contradiction to Applicants provisional application (see first paragraph under Summary of the Invention on page 1; see also claim 1 on page 53), their published International Application WO 2005/007871 A2 (paragraph 0004), and the current specification. Specifically, the specification states:

“The invention provides methods of identifying candidate psychiatric patients or patients with movement disorder for treatment with medication that acts at the D2 dopamine receptor. The method comprises determining a patient's D2 dopamine receptor (DRD2) genotype. Patients having the Taq1A (A1) allele (*A1+ allelic status*) ***are candidates for treatment with high dose of high D2 dopamine receptor binding antipsychotics and/or SSRIs that influence D2 dopamine receptor density.*** Patients lacking the Taq1A allele (*A1- allelic status*) ***are not likely to respond well to these SSRIs, and are candidates for treatment with lowdose of low D2 dopamine receptor binding or low dose high D2 dopamine receptor binding atypical antipsychotics.***”

Specification, paragraph 0004 (emphasis added).

The specification provides the following definitions:

“As used herein, "high dose" of medication means more than the chlorpromazine equivalent per kilogram (kg) of body weight (CPZEK) of about 10. (Given an average adult patient body weight of 70 kg.) One mg risperidone is equipotent to 100 mg chlorpromazine, 100 mg thioridazine, or 2 mg haloperidol. For example, a high dose of risperidone is about 6 mg/day or more for an adult patient.

As used herein, "high D2 dopamine receptor binding" or "high binding" antipsychotics means having an affinity for the D2 dopamine receptor exhibiting a $K_{sub.i}$ of less than 10 nM, as measured by in vitro radioligand binding (See, .g., Levant, 1997, Pharmacological Reviews, 49(3):231-252). This class of antipsychotic medications is often referred

Art Unit: 1639

to in the art as "typical" antipsychotics. Representative examples include risperidone (resperidone), flupenthixol, gluphenthazine decanoate, zuclopenthixol, haloperidol, thiondazine, thiotthixene and trofluperazine.

As used herein, "low dose" of medication means less than a CPZEK of less than about 7. For example, a low dose of risperidone is less than about 5 mg/day for an adult patient.

As used herein, "low D2 dopamine receptor binding" or "low binding" antipsychotics means having an affinity for the D2 dopamine receptor exhibiting a $K_{sub.i}$ of greater than 15 nM, as measured by in vitro radioligand binding (See, e.g., Levant, 1997, Pharmacological Reviews, 49(3):231-252). This class of antipsychotic medications is often referred to in the art as "atypical" antipsychotics. Representative examples include Olanzapine and Clozapine."

Specification, paragraphs 0017-0020.

Furthermore, none of the portions of the specification that Applicants point to in their Reply clearly suggest the current claim language. Applicants selective interpretation of the specification in finding support is improper.

The rejection is maintained.

Claim Rejections - 35 USC § 101 – Withdrawn

The rejection of claims 1, 2, 5 and 6, under 35 U.S.C. § 101 is withdrawn in view of Applicants' amendment to the claims.

Claim Rejections - 35 USC § 103 – Maintained

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. § 103(a) are summarized as follows:

Art Unit: 1639

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1, 2 5,7 and 8 are obvious over Suzuki #1, Suzuki #2 and Turrone:

The rejection of claims 1, 2 and 5, and new claims 7 and 8, are rejected under 35 U.S.C. § 103(a) as being unpatentable over Suzuki *et al.*, *Pharmacogenetics* 10(4):335-341 (2001)¹ (hereinafter “Suzuki #1”), in view of Suzuki *et al.*, *Am. J. Psychiatry* 158(10):1714-1716 (2001) (hereinafter “Suzuki #2”), and Turrone *et al.*, *Am. J. Psychiatry* 159(1):133-135 (2002), is maintained.

Applicants allege that there is a gap between the teachings of each of the references, and that the purported deficiency in Suzuki #1 can not be remedied by Suzuki #2, Turrone or Bourin.

In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992).

In this case, it is quite clear that Suzuki #1 suggests that the A1+ allele is a likely marker for the determination of treatment options (see captioned section below). Considering that the older typical antipsychotics and high dose antipsychotics were known to have positive effects on A1+ allele patients, one of ordinary skill in the art would have recognized the fact that newer low dose atypical antipsychotics would also serve the same purpose, and have some of the same effects as pointed out by Turrone. Additionally, Turrone shows the advantages that these drugs can avoid the side effects of elevated prolactin levels.

Reiterated Rejection:

Claim 1 is directed to a method for identifying a candidate psychiatric patient for treatment with antipsychotic or antidepressant medication that acts on DRD2, comprising

Art Unit: 1639

determine the A1+ genotype, wherein an A1+ genotype is indicative of a candidate for treatment with low dose DRD2 binding atypical antipsychotics and/or SSRIs that increase D2 dopamine receptor density; and an A1- genotype is indicative of a candidate for treatment with high dose D2 dopamine receptor binding atypical antipsychotics or alternative antidepressant.

It is known that the human DRD2 gene contains a *TaqI* restriction fragment, and that persons having at least one A1 allele show lower DRD2 density in the striatum and caudate nuclei, with diminished dopaminergic activity and reduced glucose metabolism in brain regions with abundant dopamine receptors (Suzuki #1, pages 2 and 3). Suzuki #1 describes the basis for his study on understanding the differences between clozapine and nemonapride and their potential for therapeutic treatment based on *TaqIA* polymorphism:

“Based on these data of the lower density and reduced function of DRD2 in the subjects with *A1* alleles, the DRD2 occupancy in neuroleptic-treated schizophrenic patients with *A1* alleles may be different from that in patients with no *A1* allele. This leads to the hypothesis that the *TaqI* A polymorphism is related to therapeutic response to antipsychotic drugs in the treatment of schizophrenia.”

Introduction, last two sentences of the third paragraph; and:

“In addition, clozapine has a relatively weak affinity for DRD2 compared with a strong binding activity for 5-HT_{2A}, 5-HT_{2C}, acetylcholine and histamine receptors (Schotte et al., 1995). Therefore, a study design using a fixed-dose of a selective DRD2 antagonist is preferable to clarify the association between DRD2 polymorphisms and neuroleptic response.”

Introduction, last two sentences of the fourth paragraph.

In the study, Suzuki #1 reports the results wherein candidate psychiatric patients having the *TaqI* genotype was determined as either A1 positive or A1 negative, and studied their response to nemonapride. Suzuki observed that the A1+ patients responded better to treatment for schizophrenia (as in claim 2) using nemonapride than those patients that were A1- (see *Discussion* on pages 6-8, see especially the third and fourth paragraphs in this section). Suzuki #1 states:

¹ The copy of this reference was provided by Applicants from an HTML source; accordingly, the pages as printed (10 pages from the website) do not correspond to the published journal pages.

Art Unit: 1639

“In conclusion, the present results suggest that the *TaqI A DRD2 polymorphism is related to an early therapeutic response to nemonapride in schizophrenic patients*, possibly by modifying the efficiency of DRD2 antagonism of the drug in the central nervous system. *The identification of the TaqI A DRD2 genotypes may be a pharmacodynamic marker for the prediction of therapeutic effects of antipsychotic agents before initiating drug treatment.*”

Suzuki #1, page 8, final paragraph (emphasis added).

As in claims 7 and 8, Suzuki #1 takes the sample from patient blood and using PCR for the genotyping (see page 337).

Although Suzuki #1 generally teaches that schizophrenic patients having the A1+ allele are candidates for nemonapride treatment, and that nemonapride affects the plasma levels of prolactin, it is not explicitly taught in the reference to use a “low dose” or “high dose” drug based on A1+ allele (as in claim 1), or that risperidone is such a compound (as in claim 5).

Suzuki #2 is similarly related, and discloses the results of a clinical study that determined the effects of nemonapride on patients with TaqI A polymorphism. Suzuki #2 found:

“We recently reported that *patients with schizophrenia who had the A1 allele showed greater prolactin response* (16) and better therapeutic response (17) to nemonapride, a selective dopamine antagonist, than patients without this allele. These findings indicate that A1 carriers show higher DRD2 blockade by neuroleptic drugs than noncarriers.”

Suzuki #2, page 1715, paragraph bridging cols. 1 and 2 (emphasis added); and:

“A possible clinical implication of our findings are that A1 carriers could receive potentially lower doses of neuroleptics if this polymorphism were used in a pharmacogenomic screening procedure.”

Suzuki, page 1715, col. 2, last paragraph (emphasis added).

Turrone teaches that clozapine, unlike typical antipsychotics, does not elevate prolactin levels, and has important pharmacodynamics different than risperidone (page 133, col. 1, first paragraph). The results of prolactin levels of schizophrenic patients receiving 3 mg of risperidone (*i.e.*, “low dose” as defined by Applicants’ own specification – see paragraph 0019 on page 2) are shown in Figure 1 on page 134, and show the largest increase in prolactin levels at low dosages.

Art Unit: 1639

One of ordinary skill in the art would have had a reasonable expectation of success in arriving at the invention as claimed because each of Suzuki #1, Suzuki #2 and Turrone is directed towards treating schizophrenia. One of ordinary skill in the art would have understood the advantages of using a genetic screening based on A1+ allele determination for drug administration because Suzuki #1 shows that nemonapride, a drug that binds highly with DRD2, is substantially more effective in treating patients with the A1+ allele than the A1- allele. Based on the relationship between dosages illustrated by Suzuki #2 and Turrone, one of ordinary skill in the art would have had the requisite guidance for dosage administration, and understood how drugs, like nemonapride and clozapine, having different therapeutic effects based on the A1 allele, and are useful to treat symptoms of schizophrenia. Therefore, the invention as a whole was *prima facie* obvious at the time it was made.

Claims 1, 2 and 5-8, are obvious over Suzuki #1, Suzuki #2, Turrone and Bourin:

The rejection of claims 1, 2 and 5-8, under 35 U.S.C. 103(a) as being unpatentable over Suzuki #1, Suzuki #2 and Turrone, as applied to claims 1, 2 and 5 above, and further in view of Bourin *et al.*, *CNS Drug Reviews* 7(1):25-47 (2001), is maintained for the reasons presented in the rejection immediately above.

The limitations of claims 1, 2 and 5, and the corresponding teaching of the art, are found in the rejection above and are hereby incorporated into the instant rejection.

As required by claim 6, neither Suzuki #1, Suzuki #2 or Turrone explicitly suggest to use paroxetine.

Bourin provides a review article on paroxetine, a compound for treating depression and anxiety, and teaches that is considered a well-tolerated drug (page 26, third paragraph in the section *Introduction*), discloses that it is one of the most potent inhibitor of 5-HT reuptake of available antidepressants (page 27, third paragraph), and that the compound does not interact with the dopamine D2 receptor:

“Both, in vitro and in vivo studies have demonstrated that paroxetine is devoid of any significant affinity for adrenoceptors (α_1 , α_2 , β), dopamine (D2) receptors, histamine (H1) receptors, or 5-HT receptor subtypes (5-HT1A, 5-HT2).”

Art Unit: 1639

Bourin, page 28, third paragraph.

One of ordinary skill in the art would have had a reasonable expectation of success in arriving at the invention as claimed because each of the references are directed to psychiatric treatment of psychotic and/or psychiatric disorders. One of ordinary skill in the art would have recognized that due to the safety and success in treatment with paroxetine, that monitored treatment with paroxetine in addition to low dose binding DRD2 binding agents would provide added treatment for anxiety and/or depression that often accompanies many psychotic disorders, such as schizophrenia. Therefore, the invention as a whole was *prima facie* obvious at the time it was invented.

Common Ownership of Claimed Invention Presumed

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the Examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the Examiner to consider the applicability of 35 U.S.C. § 103(c) and potential 35 U.S.C. §§ 102(e), (f) or (g) prior art under 35 U.S.C. § 103(a).

Conclusions

No claim is allowable.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action (*i.e.*, over claims 7 and 8). Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

Art Unit: 1639

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeff Lundgren whose telephone number is 571-272-5541. The Examiner can normally be reached from 7:00 AM to 5:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low, can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JSL

/ Christopher S. F. Low /
Supervisory Patent Examiner, Art Unit 1636